<DOC>
	<DOCNO>NCT01370655</DOCNO>
	<brief_summary>This study do evaluate antihypertensive efficacy tolerability MK-7145 participant mild-to-moderate hypertension . The primary hypothesis study follow : 1 . Multiple dose administration 6-mg MK-7145 result reduction systolic blood pressure ( SBP ) male participant mild moderate hypertension superior placebo , measure time weighted average change baseline 24 hour postdose ( TWA0-24hrs ) dose Day 28 2 . Multiple dose administration 6-mg MK-7145 result reduction SBP male participant mild moderate hypertension similar hydrochlorothiazide ( HCTZ ) , measure TWA0-24hrs dosing Day 28 3 . The effect MK-7145 HCTZ natriuresis ( UNaV ) well SBP diastolic blood pressure ( DBP ) , measure TWA0-24hrs , estimate 4 . Multiple dose administration MK-7145 4 week generally safe well-tolerated .</brief_summary>
	<brief_title>A Study MK-7145 Compared Placebo Hydrochlorothiazide Lowering Blood Pressure Male Participants With Hypertension ( MK-7145-009 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Inclusion criterion : Diagnosis essential hypertension Body mass index ( BMI ) ≤35 kg/m^2 Participant general good health No history clinically significant arrhythmia clinically significant abnormality electrocardiogram ( ECG ) No history clinically significant cardiac disease Treatmentnaïve take 2 antihypertensive therapeutic agent Nonsmoker and/or use nicotine nicotinecontaining product least 6 month Exclusion criterion : Participant low plasma potassium History stroke , chronic seizure , major neurological disorder History clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases History osteoporosis Active history nephrocalcinosis , nephrolithiasis hypercalciuria Orthostatic change vital sign measurement go semirecumbent stand position accompany symptoms Functional disability interfere rise semirecumbent position stand position History malignant neoplastic disease . Exceptions : ( 1 ) adequately treat nonmelanomatous skin carcinoma ; ( 2 ) malignancy successfully treat &gt; 10 year prior prestudy ( screen ) visit , ( 3 ) unlikely sustain recurrence Participant unable refrain use prescription nonprescription drug highdose aspirin ( ≥325 mg/day ) , strong/moderate Cytochrome P450 3A4 ( CYP3A4 ) inhibitor ( ritonavir , indinavir , nelfinavir , erythromycin , telithromycin , clarithromycin , chloramphenicol , fluconazole , ketoconazole , itraconazole , nefazodone , aprepitant , verapamil , diltiazem ) well strong/moderate CYP3A4 inducer ( phenytoin , carbamazepine , oxcarbazepine , phenobarbital , efavirenz , nevirapine , etravirine , rifampicin , modafinil , St Johns Wort , cyproterone , progestin ) begin approximately 2 week ( 5 halflives ) , prior administration initial dose study drug post study visit Current use nonsteroidal antiinflammatory drug ( NSAIDs ) low dose aspirin , aluminum magnesiumcontaining antacid , sucralfate , metal cation iron , multivitamins contain iron zinc discontinue least 2 week ( 5 halflives ) prior administration initial dose study drug post study visit Consumption excessive amount alcohol , define great 3 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 284 mL/10 ounce ] , wine [ 125 mL/4 ounce ] , distilled spirit [ 25 mL/1 ounce ] ) per day Participant consume excessive amount , define great 6 serving ( 1 serve approximately equivalent 120 mg caffeine ) coffee , tea , cola , caffeinated beverage per day Major surgery , donation lose 1 unit blood ( approximately 500 mL ) , participation another investigational study within 4 week prior prestudy ( screen ) History significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food Regular use illicit drug history drug abuse within approximately 6 month Dehydration volumedepletion</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>